STOCK TITAN

Polomar Health restatement adds $490K to H1 2026 loss

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Polomar Health Services, Inc. reported $3,739,944 in revenue for the nine months ended September 30, 2026, versus $16,174 a year earlier, and a net loss of $829,002, down from $1,712,193. Operating cash flow was $193,996, compared with $586,016 used in the prior-year period; cash was $254,779 at September 30, 2026. Gross margin was 45.4%.

Management said substantial doubt exists about Polomar's ability to continue as a going concern for one year from issuance, citing recurring operating losses, a history of negative operating cash flows and significant current debt. CareValidate accounted for all nine-month revenue and all accounts receivable at September 30. A new one-year CareValidate agreement took effect October 1, 2026, and renews automatically unless either party gives termination notice at least 60 days before expiration. The Audit Committee concluded that the statements for the three months ended March 31 and the three and six months ended June 30, 2026, should no longer be relied upon after identifying unrecorded commissions, purchases and interest, expenses improperly recorded to inventory, revenue recorded in the incorrect period, and Series A preferred stock classified as equity rather than mezzanine equity. The errors increased six-month net loss by $490,433; Polomar intends to file amended quarterly reports.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month revenue reached $3,739,944, versus $16,174 in 2025.
  • Moderate pointOperating cash flow was $193,996, versus $586,016 used in 2025.
  • Moderate pointNine-month net loss declined to $829,002 from $1,712,193.

Negative

  • Major pointSubstantial doubt exists about continuing as a going concern for one year.
  • Major pointRestatement increased six-month net loss by $490,433; prior statements were deemed unreliable. 24% of market cap
  • Moderate pointOne customer accounted for 100% of nine-month revenue.
Nine-month revenue $3,739,944 Nine months ended September 30, 2026; $16,174 in the comparable 2025 period.
Nine-month gross profit $1,698,032 Nine months ended September 30, 2026; $11,336 in the comparable 2025 period.
Nine-month net loss $829,002 Nine months ended September 30, 2026; $1,712,193 in the comparable 2025 period.
Operating cash flow $193,996 provided Nine months ended September 30, 2026; $586,016 used in the comparable 2025 period.
Cash $254,779 As of September 30, 2026.
Revenue concentration 100% One customer accounted for all revenue for the nine months ended September 30, 2026.
Six-month restatement adjustment $490,433 increase in net loss Correction for the six months ended June 30, 2026.
Accumulated deficit $14,565,652 As of September 30, 2026.
going concern financial
"ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
mezzanine equity financial
"Series A Preferred is classified as mezzanine equity"
Mezzanine equity is a layer of financing that sits between bank loans and full ownership, combining elements of borrowed money and equity. It often gives lenders higher potential returns in exchange for taking more risk, sometimes with the option to convert into ownership or receive extra payments; think of it as a middle seat that pays more because it’s less secure than front-row debt. Investors watch it because it affects a company’s debt risk, potential dilution of ownership, and expected returns.
paid-in-kind (PIK) dividends financial
"PIK dividends do not represent a current-period cash outflow"
performance obligation financial
"Each accepted prescription order contains a single performance obligation"
A performance obligation is a specific promise in a contract to deliver a good or provide a service to a customer, and it is the unit companies use to decide when and how much revenue to record. Think of it like checklist items in a service agreement: each item completed can trigger part of the payment to be recognized as revenue. Investors care because how obligations are identified and satisfied changes the timing and amount of reported revenue and profits, affecting comparisons and valuation.
503A regulatory
"Sec. 503A “Compounding Pharmacy”"
Section 503A is a U.S. regulatory category for traditional compounding pharmacies that prepare customized medication doses for individual patients based on a prescriber’s order. Think of it as custom tailoring for drugs: these pharmacies are treated differently from mass manufacturers, which can lower regulatory hurdles but also ties their legal standing to strict state oversight and patient-specific demand. Investors watch 503A status because it affects business models, regulatory risk, and market access for companies supplying or operating compounding services.
ASC 606 financial
"revenue in accordance with ASC 606, Revenue from Contracts with Customers"
A U.S. accounting standard that sets consistent rules for when and how companies record revenue from contracts with customers, focusing on the transfer of promised goods or services. It matters to investors because it affects the timing and amount of reported sales and profit—like deciding whether a contractor can count payment when a job starts, progresses, or finishes—so it improves comparability and helps assess a company's true economic performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were PMHS's revenue and net loss for the first nine months of 2026?

PMHS reported revenue of $3,739,944 and a net loss of $829,002 for the nine months ended September 30, 2026. In the same 2025 period, revenue was $16,174 and net loss was $1,712,193.

Why did PMHS say its 2026 quarterly financial statements should no longer be relied upon?

The Audit Committee concluded that the statements for the three months ended March 31 and the three and six months ended June 30, 2026, should no longer be relied upon after identifying unrecorded commissions, purchases and interest, expenses recorded to inventory, revenue recorded in the incorrect period, and Series A preferred stock classified as equity rather than mezzanine equity. The errors increased six-month net loss by $490,433.

Why did PMHS report substantial doubt about its ability to continue as a going concern?

Management cited recurring operating losses, a history of negative operating cash flows and significant current debt. It said continuation depends on generating revenue, raising capital and meeting obligations as they become due. Its plans include raising capital, exploring business opportunities and increasing revenue, but it gave no assurance that sufficient financing would be available on acceptable terms.

What are the terms of PMHS Series A preferred stock?

PMHS had 167 Series A preferred shares outstanding as of September 30, 2026, held by CWR 1, LLC and Reprise Management, Inc. Dividends accumulate at 10% annually and may be paid in cash or additional preferred shares. Each preferred share converts into 12,500 common shares at $0.40; voting power is capped at 19.9% of outstanding common stock until shareholder approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 Q3 0001265521 0001265521 2026-01-01 2026-09-30 0001265521 2026-11-13 0001265521 2026-09-30 0001265521 2025-12-31 0001265521 PMHS:SeriesAConvertiblePreferredStockMember 2026-09-30 0001265521 PMHS:SeriesAConvertiblePreferredStockMember 2025-12-31 0001265521 2026-07-01 2026-09-30 0001265521 2025-07-01 2025-09-30 0001265521 2025-01-01 2025-09-30 0001265521 us-gaap:CommonStockMember 2026-06-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001265521 us-gaap:RetainedEarningsMember 2026-06-30 0001265521 2026-06-30 0001265521 us-gaap:CommonStockMember 2025-06-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001265521 us-gaap:RetainedEarningsMember 2025-06-30 0001265521 2025-06-30 0001265521 us-gaap:CommonStockMember 2025-12-31 0001265521 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001265521 us-gaap:RetainedEarningsMember 2025-12-31 0001265521 us-gaap:CommonStockMember 2024-12-31 0001265521 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001265521 us-gaap:RetainedEarningsMember 2024-12-31 0001265521 2024-12-31 0001265521 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001265521 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001265521 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001265521 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001265521 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001265521 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001265521 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001265521 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001265521 us-gaap:CommonStockMember 2026-09-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001265521 us-gaap:RetainedEarningsMember 2026-09-30 0001265521 us-gaap:CommonStockMember 2025-09-30 0001265521 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001265521 us-gaap:RetainedEarningsMember 2025-09-30 0001265521 2025-09-30 0001265521 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember PMHS:TwoCustomerMember 2025-01-01 2025-12-31 0001265521 srt:RestatementAdjustmentMember 2026-01-01 2026-03-31 0001265521 srt:RestatementAdjustmentMember 2026-04-01 2026-06-30 0001265521 srt:RestatementAdjustmentMember 2026-01-01 2026-06-30 0001265521 srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-03-31 0001265521 PMHS:ReclassificationMember 2026-01-01 2026-03-31 0001265521 2026-01-01 2026-03-31 0001265521 srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0001265521 PMHS:ReclassificationMember 2026-04-01 2026-06-30 0001265521 2026-04-01 2026-06-30 0001265521 srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001265521 PMHS:ReclassificationMember 2026-01-01 2026-06-30 0001265521 2026-01-01 2026-06-30 0001265521 srt:ScenarioPreviouslyReportedMember 2026-03-31 0001265521 PMHS:ReclassificationMember 2026-03-31 0001265521 srt:RestatementAdjustmentMember 2026-03-31 0001265521 2026-03-31 0001265521 srt:ScenarioPreviouslyReportedMember 2026-06-30 0001265521 PMHS:ReclassificationMember 2026-06-30 0001265521 srt:RestatementAdjustmentMember 2026-06-30 0001265521 PMHS:RepriseNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2024-08-13 0001265521 PMHS:RepriseNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2024-08-13 2024-08-13 0001265521 PMHS:RepriseNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-06-30 2025-06-30 0001265521 PMHS:RepriseNoteMember PMHS:PromissoryNoteAndLoanAgreementMember PMHS:SeriesAConvertiblePreferredStockMember 2025-06-30 2025-06-30 0001265521 PMHS:RepriseNoteMember PMHS:PromissoryNoteAndLoanAgreementMember PMHS:SeriesAConvertiblePreferredStockMember 2025-06-30 0001265521 PMHS:RepriseNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-07-02 0001265521 PMHS:MrGordonMember 2026-06-30 0001265521 PMHS:MrGordonMember 2025-12-31 0001265521 PMHS:PromissoryNoteAndLoanAgreementMember PMHS:RepriseNoteMember 2026-09-30 0001265521 PMHS:PromissoryNoteAndLoanAgreementMember PMHS:RepriseNoteMember 2025-12-31 0001265521 us-gaap:RelatedPartyMember 2026-09-30 0001265521 PMHS:PromissoryNoteAndLoanAgreementMember PMHS:CWR1LLCMember srt:MaximumMember 2024-08-16 0001265521 PMHS:PromissoryNoteAndLoanAgreementMember PMHS:CWR1LLCMember 2024-08-16 2024-08-16 0001265521 PMHS:CWR1LLCMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-06-30 0001265521 PMHS:CWR1LLCMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-06-30 2025-06-30 0001265521 PMHS:CWRNoteIIMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-07-21 0001265521 PMHS:CWRNoteIIMember PMHS:CWRIIFirstAmendmentMember 2025-09-17 0001265521 PMHS:CWRIIFirstAmendmentMember PMHS:CWRNoteIIMember 2025-09-17 2025-09-17 0001265521 PMHS:CWRNoteIIMember PMHS:CWRIIFirstAmendmentMember 2025-07-23 2025-09-18 0001265521 PMHS:CWRNoteIIMember PMHS:CWRIIFirstAmendmentMember 2025-12-01 2026-02-27 0001265521 PMHS:CWRNoteIIMember PMHS:CWRIIFirstAmendmentMember 2026-09-30 0001265521 PMHS:CWRNoteIIMember PMHS:CWRIIFirstAmendmentMember 2025-12-31 0001265521 PMHS:CWRNoteIIMember 2026-01-01 2026-09-30 0001265521 PMHS:CWR1LLCMember 2026-09-30 0001265521 PMHS:CWR1LLCMember 2025-12-31 0001265521 PMHS:ProfescoNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-07-28 0001265521 PMHS:ProfescoNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-10-31 0001265521 PMHS:ProfescoNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-11-17 0001265521 PMHS:ProfescoNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2026-01-01 0001265521 PMHS:ProfescoNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2026-09-30 0001265521 PMHS:ProfescoNoteMember PMHS:PromissoryNoteAndLoanAgreementMember 2025-12-31 0001265521 PMHS:PolomarSpecialtyPharmacyLLCMember 2026-01-31 0001265521 PMHS:OrionSpecialtyLabsLLCMember 2026-01-01 2026-01-31 0001265521 PMHS:OrionSpecialtyLabsLLCMember 2026-06-30 0001265521 PMHS:OrionSpecialtyLabsLLCMember 2026-06-01 2026-06-30 0001265521 PMHS:DirectorAndOfficersMember 2026-09-30 0001265521 PMHS:DirectorAndOfficersMember 2026-01-01 2026-09-30 0001265521 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001265521 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001265521 us-gaap:CommonStockMember srt:BoardOfDirectorsChairmanMember 2026-01-01 2026-09-30 0001265521 us-gaap:CommonStockMember srt:BoardOfDirectorsChairmanMember 2026-09-30 0001265521 srt:ChiefExecutiveOfficerMember 2026-07-01 2026-09-30 0001265521 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001265521 srt:ChiefExecutiveOfficerMember 2026-09-30 0001265521 PMHS:ShareBasedPaymentArrangementOptionMember 2026-01-01 2026-09-30 0001265521 PMHS:TwoThousandTwentyFourPlanMember 2024-12-31 0001265521 PMHS:TwentyTwentyFourEquityIncentivePlanMember 2024-08-08 2024-08-08 0001265521 PMHS:TwentyTwentyFourEquityIncentivePlanMember 2026-07-01 2026-07-01 0001265521 PMHS:TwentyTwentyFourEquityIncentivePlanMember 2026-01-01 2026-06-30 0001265521 PMHS:TwoThousandTwentyFourPlanMember 2026-09-30 0001265521 2025-01-01 2025-12-31 0001265521 srt:MinimumMember 2026-01-01 2026-09-30 0001265521 srt:MaximumMember 2026-01-01 2026-09-30 0001265521 PMHS:ExercisePriceOneMember 2026-01-01 2026-09-30 0001265521 PMHS:ExercisePriceOneMember 2026-09-30 0001265521 PMHS:ExercisePriceTwoMember 2026-01-01 2026-09-30 0001265521 PMHS:ExercisePriceTwoMember 2026-09-30 0001265521 us-gaap:StockOptionMember 2026-07-01 2026-09-30 0001265521 us-gaap:StockOptionMember 2025-07-01 2025-09-30 0001265521 us-gaap:StockOptionMember 2026-01-01 2026-09-30 0001265521 us-gaap:StockOptionMember 2025-01-01 2025-09-30 0001265521 PMHS:ConversionOfSeriesAPreferredStockToCommonStockMember 2026-07-01 2026-09-30 0001265521 PMHS:ConversionOfSeriesAPreferredStockToCommonStockMember 2025-07-01 2025-09-30 0001265521 PMHS:ConversionOfSeriesAPreferredStockToCommonStockMember 2026-01-01 2026-09-30 0001265521 PMHS:ConversionOfSeriesAPreferredStockToCommonStockMember 2025-01-01 2025-09-30 0001265521 PMHS:PrescriptionFulfillmentMember 2026-07-01 2026-09-30 0001265521 PMHS:PrescriptionFulfillmentMember 2025-07-01 2025-09-30 0001265521 PMHS:OthersMember 2026-07-01 2026-09-30 0001265521 PMHS:OthersMember 2025-07-01 2025-09-30 0001265521 PMHS:PrescriptionFulfillmentMember 2026-01-01 2026-09-30 0001265521 PMHS:PrescriptionFulfillmentMember 2025-01-01 2025-09-30 0001265521 PMHS:OthersMember 2026-01-01 2026-09-30 0001265521 PMHS:OthersMember 2025-01-01 2025-09-30 0001265521 2026-06-01 2026-06-01 0001265521 2026-08-01 2026-08-01 0001265521 PMHS:TerrenceMTierneyMember PMHS:AmendedAgreementMember srt:MinimumMember 2026-05-12 2026-05-12 0001265521 PMHS:TerrenceMTierneyMember PMHS:AmendedAgreementMember srt:MaximumMember 2026-05-12 2026-05-12 0001265521 PMHS:TerrenceMTierneyMember PMHS:AmendedAgreementMember 2026-05-12 2026-05-12 0001265521 PMHS:AmendedAgreementMember 2026-05-12 2026-05-12 0001265521 2026-05-12 0001265521 PMHS:TerrenceMTierneyMember PMHS:AmendedAgreementMember PMHS:NonQualifiedStockOptionMember srt:MaximumMember 2026-05-12 2026-05-12 0001265521 PMHS:TerrenceMTierneyMember PMHS:AmendedAgreementMember PMHS:NonQualifiedStockOptionMember 2026-05-12 2026-05-12 0001265521 PMHS:MrTierneyMember 2026-07-01 2026-09-30 0001265521 PMHS:MrTierneyMember 2026-01-01 2026-09-30 0001265521 PMHS:LicenseAgreementMember srt:MinimumMember 2024-06-29 0001265521 srt:MaximumMember PMHS:LicenseAgreementMember 2024-06-29 0001265521 us-gaap:SubsequentEventMember 2026-11-01 2026-11-01 0001265521 us-gaap:SubsequentEventMember 2026-11-01 0001265521 us-gaap:SubsequentEventMember PMHS:NotePayableMember 2026-11-09 2026-11-09 0001265521 us-gaap:SubsequentEventMember PMHS:NotePayableMember 2026-11-09 0001265521 us-gaap:SubsequentEventMember PMHS:NotePayableMember 2026-12-31 0001265521 us-gaap:SubsequentEventMember PMHS:NotePayableMember 2026-12-31 2026-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PMHS:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2026

 

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _____ to _______

 

Commission File Number: 000-56555

 

Polomar Health Services, Inc.

(Exact name of Registrant as specified in its charter)

 

Nevada   86-1006313

(State or other jurisdiction

of incorporation or organization)

 

(IRS Employer

Identification No.)

 

575 Lexington Avenue

Suite 17-143-6

New York, NY 10022

(Address of principal executive offices)

 

(727) 425-7575

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

☐ Large accelerated filer ☐ Accelerated filer
☒ Non-accelerated Filer ☒ Smaller reporting company
  ☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 28,380,868 common shares as of November 13, 2026.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
     
  PART I – FINANCIAL INFORMATION  
     
Item 1: Financial Statements (Unaudited)
     
  Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 F-1
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026, and September 30, 2025 F-2
  Condensed Consolidated Statements of Stockholders’ Deficit for the Three and Nine Months Ended September 30, 2026, and September 30, 2025 F-3
  Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2026 and September 30, 2025 F-4
  Notes to Condensed Consolidated Financial Statements F-5
     
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 3
Item 3: Quantitative and Qualitative Disclosures About Market Risk 8
Item 4: Controls and Procedures 8
     
  PART II – OTHER INFORMATION 10
     
Item 1: Legal Proceedings 10
Item 1A: Risk Factors 10
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 10
Item 3: Defaults Upon Senior Securities 10
Item 4: Mine Safety Disclosures 10
Item 5: Other Information 10
Item 6: Exhibits 10

 

2

 

 

POLOMAR HEALTH SERVICES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(Unaudited)

 

   September 30, 2026   December 31, 2025 
   (Unaudited)     
ASSETS          
Current assets          
Cash  $254,779   $132,150 
Accounts receivable   239,705    96,941 
Inventory   8,536    93,636 
Other current assets   170,540    - 
Total current assets   673,560    322,727 
Property and equipment, net   24,875    43,452 
Operating lease - right-of-use asset   170,379    14,864 
Security deposit   18,060    9,000 
Total Assets  $886,874   $390,043 
           
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable and accrued liabilities  $1,388,795   $386,983 
Unearned revenue   300,000    300,000 
Promissory notes – related parties   879,514    897,660 
Note payable – director and officer insurance   148,246    - 
Operating lease   72,895    14,864 
Other current liabilities   -    12,865 
Total current liabilities   

2,789,450

    

1,612,372

 

Long-term liabilities

          
Operating lease   97,615    - 
Total long-term liabilities   97,615    - 
Total liabilities   2,887,065    1,612,372 
Mezzanine Equity           
Series A convertible preferred stock, $0.001 par value; 5,000,000 shares authorized of which 1,000 shares is designated for Series A convertible stock; 167 and 150 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; liquidation value $5,000 per share.   835,000    750,000 
Stockholders’ deficit          
Common stock; $0.001 par value; 295,000,000 shares authorized; 28,380,868 and 28,019,624 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively.   28,381    28,020 
Additional paid-in capital   11,702,080    11,611,919 
Accumulated deficit   (14,565,652)   (13,612,268)
Total stockholders’ deficit   (2,835,191)   (1,972,329)
Total Liabilities, Mezzanine Equity and Stockholders’ Deficit  $886,874   $390,043 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-1

 

 

POLOMAR HEALTH SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

             
   For the Three Months Ended   For the Nine Months Ended 
   September 30, 2026   September 30, 2025   September 30, 2026   September 30, 2025 
                 
Revenue  $1,133,775   $6,163   $3,739,944   $16,174 
                     
Cost of goods sold   619,340    1,840    2,041,912    4,838 
                     
Gross profit   514,435    4,323    1,698,032    11,336 
                     
Operating expenses                    
General and administrative   474,367    619,032    744,433    1,588,725 
Sales and marketing   507,944    14,099    1,670,937    30,161 
Total operating expenses   982,311    633,131    2,415,370    1,618,886 
                     
Loss from operations   (467,876)   (628,808)   (717,338)   (1,607,550)
                     
Other expense                    
Interest expense   (45,674)   (20,967)   (111,664)   (104,643)
Total other expense   (45,674)   (20,967)   (111,664)   (104,643)
                     
Net loss   (513,550)   (649,775)   (829,002)   (1,712,193)
Dividend on Series A convertible preferred stock   (35,500)   -    (124,382)     
Net loss attributable to common stockholders  $(549,050)  $(649,775)  $(953,384)  $(1,712,193)
Net loss per common share: basic and diluted  $(0.02)  $(0.02)  $(0.03)  $(0.06)
Weighted average common shares outstanding – basic and diluted   28,379,781    28,008,183    28,153,781    27,779,164 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-2

 

 

POLOMAR HEALTH SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026

(Unaudited)

 

                 
   Common Stock  

Additional

Paid-In

   Accumulated   

Total

Stockholders’

Deficit

 
   Shares   Amount   Capital   Deficit   (As Restated) 
                     
Balance, June 30, 2026

(As Restated) see Note 3

   28,280,868   $28,281   $11,636,491   $(14,016,602)  $            (2,351,830)
Issuance of common stock   100,000    100    11,700    -    11,800 
Stock-based compensation   -    -    53,889    -    53,889 
Paid-in-kind Series A convertible preferred stock dividend   -    -         (30,000)   (30,000)
Dividend accrued             -    (5,500)   (5,500)
Net loss   -    -    -    (513,550)   (513,550)
Balance, September 30, 2026   28,380,868   $28,381   $11,702,080   $(14,565,652)  $(2,835,191)

 

POLOMAR HEALTH SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025

(Unaudited)

 

                 
   Common Stock   Additional
Paid-in
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Capital   Deficit   Deficit 
                     
Balance, June 30, 2025   27,945,130   $27,945   $11,591,580   $(3,973,581)  $   7,645,944 
Issuance of common stock   74,494    75    20,352    -    20,427 
Net loss   -    -    -    (649,775)   (649,775)
Balance, September 30, 2025   28,019,624   $28,020   $11,611,932   $(4,623,356)  $7,016,596 

 

POLOMAR HEALTH SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

 

   Common Stock   Additional
Paid-in
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Capital   Deficit   Deficit 
                     
Balance, December 31, 2025   28,019,624   $28,020   $11,611,919   $(13,612,268)  $    (1,972,329)
Issuance of common stock   100,000    100    11,700    -    11,800 
Stock-based compensation   -    -    53,889    -    53,889 
Stock-based compensation that was previously accrued for   261,244    261    24,572    -    24,833 
Paid-in-kind Series A convertible preferred stock dividend   -    -         (85,000)   (85,000)
Dividend paid and accrued   -    -    -    (39,382)   (39,382)
Net loss   -    -    -    (829,002)   (829,002)
Balance, September 30, 2026   28,380,868   $28,381   $11,702,080   $(14,565,652)  $(2,835,191)

 

POLOMAR HEALTH SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025

 

   Common Stock   Additional
Paid-in
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Capital   Deficit   Deficit 
                     
Balance, December 31, 2024   27,657,679   $27,658   $11,482,636   $(2,911,163)  $   8,599,131 
Issuance of common stock   361,945    362    129,296    -    129,658 
Net loss   -    -    -    (1,712,193)   (1,712,193)
Balance, September 30, 2025   28,019,624   $28,020   $11,611,932   $(4,623,356)  $7,016,596 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-3

 

 

POLOMAR HEALTH SERVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

       
   For The Nine Months Ended 
   September 30, 2026   September 30 2025 
Cash Flows from Operating Activities          
Net loss  $(829,002)  $(1,712,193)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation and amortization   18,577    777,338 
Stock-based compensation   65,689    129,658 
Right of use amortization   31,071    - 
Changes in operating assets and liabilities          
Accounts receivable   (142,764)   1,845 
Inventory   85,100    (90,033)
Security deposit   (9,060)   - 
Other current assets   17,170    - 

Other current liabilities

   (12,865)   - 
Lease liabilities   (30,940)   - 
Unearned revenue   -    200,000 
Accounts payable and accrued liabilities   1,001,020    107,369 
Net cash provided by (used in) operating activities   193,996    (586,016)
           
Cash flows from investing activities   -    - 
Net cash provided by (used in) investing activities   -    - 
           
Cash Flows from Financing Activities          
Payments on promissory notes – related parties   (18,146)   - 
Proceeds from promissory notes – related party   -    618,679 
Payments on note payable – director and officer insurance   (39,464)   - 
Dividend paid   (13,757)   - 
Net cash (used in) provided by financing activities   (71,367)   618,679 
Net increase in cash   122,629    32,663 
Cash, beginning of period   132,150    6,191 
Cash, end of period  $254,779   $38,854 
Supplemental disclosure of non-cash investing and financing activities          
Stock-based compensation that was previously accrued for  $24,833   $- 
Accrued dividends  $25,625   $- 
Operating lease assets and liabilities  $186,586   $- 
Paid-in-kind dividend  $ 85,000   $- 
Note payable – director and officer insurance  $187,710   $

-

 
Supplemental disclosure of cash flow information          
Cash paid for interest  $3,589   $104,643 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-4

 

 

POLOMAR HEALTH SERVICES, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2026

 

NOTE 1 – NATURE AND DESCRIPTION OF BUSINESS

 

Polomar Health Services, Inc. (the “Company”), operates Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy, located in Palm Harbor, FL, pursuant to license # PH35196 (“Polomar Pharmacy”). Polomar Pharmacy is also licensed as a Special Sterile Compounding Pharmacy, permit #PH35277, which authorizes the licensed entity to dispense injectable and other sterile compounds (eye drops, infused therapeutics) upon receipt of a valid prescription. The compounding facility operates pursuant to guidelines established under Sec. 503A “Compounding Pharmacy” of the Federal Food, Drug and Cosmetic Act. Section 503A authorizes the licensed entity to manufacture compounded drugs and fulfill prescriptions provided to it by state licensed physicians and other licensed healthcare professionals including physician assistants and nurse practitioners. The Company is presently licensed and authorized to fulfill and deliver compounded prescribed medications in 24 states.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the period presented have been reflected herein.

 

The accompanying unaudited condensed consolidated financial statements as of September 30, 2026, and for the three and nine months ended September 30, 2026 and September 30, 2025, have been prepared by the Company, without audit, in accordance with the rules and regulations of the United States (“U.S.”) Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted in accordance with such rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, necessary to state fairly the financial position of the Company and its results of operations and cash flows as of and for the periods presented. These financial statements should be read in conjunction with the annual audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, that was filed with the SEC on May 22, 2026.

 

It is management’s opinion, however, that all material adjustments (consisting of normal and recurring adjustments) have been made which are necessary for a fair presentation of the financial statements. The results for the interim period are not necessarily indicative of the results expected for the year.

 

Consolidation

 

The financial statements include the accounts of the Company and its wholly owned subsidiary, Polomar Pharmacy. All significant intercompany balances and transactions have been eliminated.

 

Going Concern and Liquidity

 

Liquidity refers to the Company’s ability to meet its anticipated cash requirements, including funding ongoing operations, satisfying contractual obligations, and paying other ordinary-course business expenses. The Company’s primary cash requirements consist of operating expenses, general and administrative expenses, payroll, vendor payments, and other costs associated with conducting its business.

 

The Company’s primary sources of liquidity have historically been proceeds from debt and equity financings, together with cash flows generated from operating activities. The Company has relied primarily on external financing to fund its operations and satisfy its working capital requirements.

 

The Company’s ability to meet its future cash requirements will depend on its ability to generate sufficient cash flows from operations, effectively manage operating expenses, and obtain additional financing through debt or equity issuances, as necessary. There can be no assurance that additional financing will be available when required or on terms acceptable to the Company.

 

Management continues to monitor the Company’s cash position, working capital requirements, and operating expenditures and evaluate available financing alternatives to support ongoing operations. If the Company is unable to generate sufficient cash flows from operations or secure additional financing, it may need to reduce or defer certain expenditures, which could adversely affect its business, financial condition, and results of operations.

 

Under Accounting Standards Codification “ASC”, ASC 205-40, Presentation of Financial Statements, Going Concern, management is required to evaluate at each annual and interim reporting period whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued, and, if substantial doubt is raised, whether our plans to mitigate those conditions, when considered in the aggregate, alleviate that doubt.

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

 

F-5

 

 

Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the financial statements are issued and determined that substantial doubt exists about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on the Company’s ability to generate revenue, raise capital and the ability to meet its obligations as they become due, within a year from the date of issuance of these financial statements. Management assessed that there were such conditions and events, including a history of recurring operating losses, a history of negative cash flows from operating activities, and significant current debt. As of September 30, 2026, the Company has cash and cash equivalents of $254, 779 and an accumulated deficit of $14,565,652. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date of filing of the financial statements. Management’s plans are to raise additional capital, explore potential business opportunities, and to increase revenue. However, there is no assurance that the Company will raise sufficient capital to continue operations or be on acceptable terms. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

 

Cash and Cash Equivalents

 

Cash consists of deposits maintained at two large financial institutions. The Company did not hold any cash equivalents as of September 30, 2026, or December 31, 2025. Cash equivalents are defined as highly liquid investments with original maturities of three months or less at the date of purchase that are readily convertible to known amounts of cash.

 

Management believes the credit risk associated with these deposits is minimal and has not experienced any losses related to these accounts.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. For the three and nine months ended September 30, 2026, all of the Company’s revenue came from one source. Under its Pharmacy Services and Compounding Agreement with CareValidate, Inc. (“CareValidate”), the Company fulfills prescriptions for compounded medications, principally sterile compounded GLP-1 agonists for subcutaneous injection. The Company applies the five-step model as follows:

 

Step 1 – Identify the contract with the customer. The Company considers CareValidate, not the individual patient, to be its customer. CareValidate contracts for the Company’s fulfillment services on behalf of patients treated through its telehealth network, and CareValidate is obligated to pay the Company. The Services Agreement sets the framework terms: pricing, fulfillment standards, and payment terms. It does not require CareValidate to submit any minimum volume of prescriptions. The Company therefore concludes that a contract exists under ASC 606 when CareValidate submits a valid prescription order and the Company accepts it. At that point, the medication to be dispensed, the price, and the payment terms are identifiable, and collection is probable.

 

Step 2 – Identify the performance obligations. Each accepted prescription order contains a single performance obligation: compounding, dispensing, and delivering the prescribed medication to the patient. Compounding, pharmacist verification, labeling, packaging, and shipping are not distinct from one another. They are inputs the Company combines to deliver one finished, dispensed prescription. Shipping takes place before control of the medication transfers, so it is a fulfillment activity rather than a separate performance obligation. Shipping costs are recorded in sales and marketing expense. The Company provides no warranties other than assurance that the medication meets its prescribed specifications.

 

Step 3 – Determine the transaction price. The transaction price is the fixed per-prescription fee in the Services Agreement’s fee schedule, which varies by medication, dosage, and supply quantity. The Company does not offer rebates, volume discounts, or price concessions. It does not accept returns of dispensed medications except for replacement of damaged or nonconforming product, which has been immaterial. As a result, the transaction price contains no material variable consideration. Payment is due within 15 days of invoicing. However, the Company can receive accelerated payments under a finance arrangement, generally 3%, if cash is needed to fund operations.

 

A third party that is not affiliated with the Company provides account management services and earns commissions based on the Company’s revenue. The Company acts as principal in its prescription fulfillment arrangements for four reasons:

 

  ● It holds the pharmacy and sterile compounding licenses.
  ● It compounds the medication and controls it before it transfers to the patient.
  ● It bears inventory risk.
  ● It is primarily responsible for fulfillment.

 

Revenue is therefore presented gross. The commissions are not consideration payable to a customer and are recorded in sales and marketing expense. Each contract has a duration of less than one year, so the Company applies the practical expedient in ASC 340-40 and expenses commissions as incurred.

 

Step 4 – Allocate the transaction price. Each prescription order has a single performance obligation, so the entire transaction price is allocated to that obligation. No allocation based on standalone selling prices is required.

 

Step 5 – Recognize revenue when or as the performance obligation is satisfied. Revenue is recognized at a point in time, when control of the medication transfers. The Company has determined this occurs upon shipment from its Palm Harbor, Florida facility. At that point, the Company has a present right to payment, and physical possession and the risks of ownership have passed. The Company invoices CareValidate monthly. Accounts receivable are recorded when the Company’s right to payment becomes unconditional.

 

Inventory

 

Inventory consists of raw materials and is stated at the lower of cost or net realizable value. Cost is determined using the weighted-average cost method. Management periodically reviews inventory for excess, obsolete, or slow-moving items and records reserves to reduce the carrying value of such inventory to its estimated net realizable value. Such estimates are based on historical usage, future demand, market conditions, and other factors. As of September 30, 2026 and December 31, 2025, there is no inventory reserve.

 

Stock-Based Compensation

 

The Company measures all equity-based payment arrangements to employees, directors, and non-employee consultants in accordance with ASC 718, Compensation - Stock Compensation. The grant-date fair value of stock-based awards is determined using either the quoted market price of the Company’s Common Stock or the Black-Scholes option valuation model, as appropriate for the instrument type.

 

Compensation cost for service-based awards is recognized on a straight-line basis over the requisite service period.

 

The Black-Scholes option model incorporates the following assumptions: expected term (using the simplified method as the average of contractual term and vesting period); expected stock price volatility (based on the Company’s historical stock price); risk-free interest rates (based on U.S. Treasury rates for maturities approximating expected lives); and expected dividend yield of zero (as the Company has not paid dividends and does not anticipate doing so in the foreseeable future). Changes in assumptions used to estimate fair value could result in materially different results.

 

F-6

 

 

Earnings Per Share

 

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share (“EPS”) calculations are determined by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. In calculating net income (loss) attributable to common stockholders, dividends declared or accrued on the Series A Preferred including dividends payable in kind (“PIK”), are deducted from net loss to determine net loss attributable to common stockholders.

 

PIK dividends represent dividends declared on the Company’s preferred stock that are satisfied through the issuance of additional shares of the Series A Preferred rather than through the payment of cash. PIK dividends are included in the calculation of loss attributable to common stockholders in the period in which they are declared or accrued for, consistent with the terms of the Series A Preferred.

 

Accordingly, accrued cash dividends and PIK dividends increase the loss available to common stockholders for purposes of calculating basic and diluted EPS, as applicable. PIK dividends do not represent a current-period cash outflow but increase the carrying amount and/or number of shares of the applicable preferred stock in accordance with the terms of the Series A Preferred.

 

Fair Value Measurements

 

The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

 

Level 1: Quoted prices for identical assets or liabilities in active markets.

 

Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

Level 3: Valuations derived from techniques in which one or more significant inputs are unobservable.

 

As defined by ASC 820, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale, which was further clarified as the price that would be received to sell an asset or paid to transfer a liability (“an exit price”) in an orderly transaction between market participants at the measurement date.

 

The reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of factors and assumptions. Accordingly, certain fair values may not represent actual values of the Company’s financial instruments that could have been realized, or that will be recognized in the future, and do not include expenses that could be incurred in an actual settlement.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, accounts payable, accrued liabilities, and related-party and third-party notes payable approximate fair value due to their relatively short maturities. The Company’s notes payable to related parties are recorded at their carrying amounts as of September 30, 2026 and December 31, 2025. Due to the related-party nature of these arrangements, the terms and conditions may differ from those that would be available in transactions with unrelated third parties.

 

F-7

 

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. The income tax provision for interim periods is determined using an estimated annual effective tax rate, adjusted for discrete items recognized in the period in which they occur.

 

As of September 30, 2026, and December 31, 2025, the Company maintained a full valuation allowance against its net deferred tax assets, as management concluded that it is more likely than not that these deferred tax assets will not be realized. The assessment of the need for a valuation allowance requires management to evaluate all available positive and negative evidence, including the Company’s history of operating results, cumulative losses in recent years, expectations of future taxable income, the reversal of existing temporary differences, and available tax planning strategies.

 

Pursuant to Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), a corporation that undergoes an “ownership change,” generally defined as a cumulative increase of more than 50 percentage points in the stock ownership of 5% shareholders within a rolling three-year period may have its ability to utilize pre-change net operating loss carryforwards and certain other tax attributes significantly limited on an annual basis. The Company has not performed a Section 382 limitations analysis.

 

The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of September 30, 2026, and December 31, 2025, the Company did not have any uncertain tax positions.

 

Segment Reporting

 

The Company operates as one reportable segment, a specialty pharmacy under ASC 280, Segment Reporting. The chief operating decision maker “CODM”, the Company’s Interim Chief Executive Officer, reviews financial performance primarily using operating income (loss), which is consistent with the presentation in the Company’s unaudited condensed consolidated statements of operations. The CODM monitors revenues and operating expenses by segment for purposes of strategic decision-making and resource allocation, including the evaluation of the timing and amount of future investment in, or development of, the Company’s products. The expense categories reviewed by the CODM are consistent with those presented in the unaudited condensed consolidated statements of operations.

 

Concentration

 

The Company’s revenue is highly concentrated with one customer located in the United States. This customer accounted for all of the Company’s total revenue for the three and nine months ended September 30, 2026.

 

As of September 30, 2026, one customer accounted for all of the Company’s total accounts receivable and as of December 31, 2025, two customers accounted for 100% of the Company’s total accounts receivable.

 

For the three and nine months ended September 30, 2026, the Company utilizes an unaffiliated third-party vendor to fulfill performance obligations to its customer. This vendor earns commissions based on the Company’s revenue. Although the Company remains responsible for fulfilling its performance obligations to customers, the loss of this vendor relationship, or a material change in its terms, could have a material adverse effect on the Company’s financial position, results of operations, and cash flows.

 

The Company relies on four primary vendors, providing the following services and purchases:

 

  ● Shipping logistics
  ● Product testing
  ● Active pharmaceutical ingredients
  ● Packaging

 

Recent Accounting Pronouncements

 

Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future financial statement presentation or disclosures.

 

In December of 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), Narrow-Scope Improvements. This ASU consolidates required interim disclosures into a single, accessible list within ASC 270. This ASU applies to interim reporting periods within annual reporting periods beginning after December 15, 2027. Management is currently evaluating the effect of this pronouncement on its disclosures.

 

In December of 2025, the FASB issued ASU 2025-12, Codification Improvements. This ASU addresses issues to refine U.S. GAAP, including clarifying diluted EPS calculations during losses, refining derivative scope, correcting technical errors in financial statement descriptions, and amending share-based consideration payable to customers, diluted EPS and lease receivables. This ASU applies to fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Management is currently evaluating the effect of this pronouncement on its disclosures.

 

In April 2026, the FASB issued ASU 2026-01, Equity (Topic 505): Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock. This ASU addresses how an issuer should initially measure paid-in-kind (“PIK”) dividends on equity-classified preferred stock and requires that such dividends be initially measured based on the PIK dividend rate stated in the preferred stock agreement. ASU 2026-01 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company intends to early adopt ASU 2026-01 effective for its annual reporting period ending December 31, 2026, applying the amendments on modified retrospective basis to Series A Preferred Stock outstanding as of the date of initial application, with a cumulative-effect adjustment to accumulated deficit as of the beginning of the period of adoption]. The Company is currently evaluating whether the adoption to have a material impact on its financial statements.

 

F-8

 

 

NOTE 3 – RECLASSIFICATION AND RESTATEMENT

 

Reclassification

 

Certain amounts in the prior-period financial statements have been reclassified to conform to the current-period presentation. These reclassifications primarily relate to the classification of certain expenses between cost of sales and general and administrative expenses, selling and marketing expenses, and interest expense.

 

During the three months ended September 30, 2026, the Company changed the presentation of the cost of goods sold, general and administrative expenses and selling and marketing expenses within its unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2026. The Company believes this presentation better reflects the nature of these items and provides more useful information to users of the financial statements. To conform to the current period presentation, certain amounts in the previously reported unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2026, as filed in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, have been reclassified. These reclassifications had no effect on previously reported net income (loss), net income (loss) per share, total assets, total liabilities, stockholders’ deficit, or cash flows. The amounts for the three and nine months ended September 30, 2026, presented in this Quarterly Report on Form 10-Q reflect the current presentation.

 

Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements

 

On November 1, 2026, the Audit Committee of the Board of Directors of the Company after discussion with management, concluded that the Company’s unaudited condensed consolidated financial statements for the following periods (the “Non-Reliance Periods”) should no longer be relied upon:

 

  ● The three months ended March 31, 2026, included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on June 1, 2026; and
     
  ● The three and six months ended June 30, 2026, included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2026.

 

This conclusion was disclosed in the Company’s Current Report on Form 8-K filed on November 3, 2026. Investors should also no longer rely on any earnings releases, investor presentations or other communications that describe these financial statements.

 

While preparing its financial statements for the three and nine months ended September 30, 2026, management identified the following errors in the Non-Reliance Periods:

 

  ● Commissions, purchases and interest expense that were incurred but not recorded;
  ● Expenses improperly recorded to inventory;
  ● Revenue recorded in the incorrect period; and
  ● Classification of the Series A Preferred as equity rather than mezzanine equity.

 

Correcting these errors increased net loss by $393,551 for the three months ended March 31, 2026, and $96,882 for the three months ended June 30, 2026, for a total of $490,433 for the six months ended June 30, 2026.

 

Management evaluated the errors under ASC 250, Accounting Changes and Error Corrections, and SEC Staff Accounting Bulletin Nos. 99 and 108, and concluded that they were material to the Non-Reliance Periods. The Company intends to file amended Quarterly Reports on Form 10-Q/A restating these periods as soon as practicable. Management is also reassessing its disclosure controls and procedures and its internal control over financial reporting.

 

The financial statements in this Quarterly Report reflect the corrections, with each expense recorded in the period in which it was incurred. As a result, expenses relating to the Non-Reliance Periods are included in the nine months ended September 30, 2026, but not in the three months ended September 30, 2026. The March 31 and June 30, 2026, quarterly periods in the statements of stockholders’ deficit have been restated. The errors did not affect the consolidated balance sheet as of December 31, 2025, results of operations for the three and nine months ended September 30, 2025, or net cash flows from operating, investing or financing activities, for any period.

 

The following tables present the effects of the reclassification and restatement on the Company’s previously issued financial statements for the Non-Reliance Periods.

 

Condensed Consolidated Statements of Operations

Three Months Ended March 31, 2026

(Unaudited)

 

   As Previously Reported   Reclassification   Restatement Adjustment  

As

Restated

 
Revenue  $1,005,519   $-   $51,368   $1,056,887 
Cost of goods sold   455,030    (7,902)   260,035    707,163 
Gross profit   550,489    7,902   (208,667)   349,724 
Operating expenses                    
General and administrative   245,934    (101,033)   -    144,901 
Sales and marketing   311,457    108,935    175,594    595,986 
Total operating expenses   557,391    7,902   175,594    740,887 
Loss from operations   (6,902)   -    (384,261)   (391,163)
Other Expense                    
Interest expense   18,475    -    9,290    27,765 
Total other expense   18,475    -    9,290    27,765 
Net loss   (25,377)   -    (393,551)   (418,928)
Dividend on Series A convertible preferred stock   -    -    -    - 
Net loss attributable to common stockholders  $(25,377)   -   $(393,551)  $(418,928)
Net loss per common share: basic and diluted  $(0.00)   

-

   $(0.01)  $(0.01)
Weighted average common shares outstanding – basic and diluted   28,022,626    

-

    28,022,626    28,022,626 

 

F-9

 

 

Condensed Consolidated Statements of Operations

Three Months Ended June 30, 2026

(Unaudited)

 

   As Previously Reported   Reclassification   Restatement Adjustment  

As

Restated

 
Revenue  $1,528,705   $-   $20,577   $1,549,282 
Cost of goods sold   592,788    53,692    68,929    715,409 
Gross profit   935,917    (53,692)   (48,352)   833,873 
Operating expenses                    
General and administrative   261,125    (135,960)   -    125,165 
Sales and marketing   456,419    68,845    41,743    567,007 
Total operating expenses   717,544    (67,115)   41,743    692,172 
Income (loss) from operations   218,373    13,423    (90,095)   141,701 
Other expenses                    
Interest expense   18,015    13,423    6,787    38,225 
Total other expense   18,015    13,423    6,787    38,225 
Net income (loss)   200,358    -    (96,882)   103,476 
Dividend on Series A convertible preferred stock   (88,882)   -    -    (88,882)
Net income (loss) attributable to common stockholders   111,476    -    (96,882)   14,594 
Net income (loss) per common share: basic and diluted  $0.00    -   $(0.00)  $0.00 
Weighted average common shares outstanding – basic and diluted   28,055,593    -    28,055,593    28,055,593 

 

Condensed Consolidated Statements of Operations

Six Months Ended June 30, 2026

(Unaudited)

 

   As Previously Reported   Reclassification   Restatement Adjustment  

As

Restated

 
Revenue  $2,534,224   $-   $71,945   $2,606,169 
Cost of goods sold   1,047,818    45,790    328,964    1,422,572 
Gross profit   1,486,406    (45,790)   (257,019)   1,183,597 
Operating expenses                    
General and administrative   507,059    (236,993)   -    270,066 
Sales and marketing   767,876    177,780    217,337    1,162,993 
Total operating expenses   1,274,935    (59,213)   217,337    1,433,059 
Income (loss) from operations   211,471    13,423    (474,356)   (249,462)
Other expenses                    
Interest expense   36,490    13,423    16,077    65,990 
Total other expense   36,490    13,423    16,077    65,990 
Net income (loss)   174,981    —    (490,433)   (315,452)
Dividend on Series A convertible preferred stock   (88,882)   —    -    (88,882)
Net income (loss) attributable to common stockholders   86,099    —    (490,433)   (404,334)
Net income (loss) per common share: basic and diluted  $0.00   $-   $(0.02)  $(0.01)
Weighted average common shares outstanding – basic and diluted   28,038,909    

-

    28,038,909    28,038,909 

 

F-10

 

 

Condensed Consolidated Balance Sheet

As of March 31, 2026

(Unaudited)

 

   As Previously Reported   Reclassification   Restatement Adjustment  

As

Restated

 
Accounts receivable  $170,851   $-   $51,368   $222,219 
Total Assets  $516,600   $-   $51,368   $567,968 
Accrued expenses and other current liabilities  $624,315   $-   $437,266   $1,061,581 
Promissory notes – related parties   818,952    -    7,653    826,605 
Total current liabilities   1,762,118    -    444,919    2,207,037 
Mezzanine equity   -    750,000    -    750,000 
Additional paid-in capital   12,364,074    (750,000)   -    11,614,074 
Accumulated deficit   (13,637,645)        (393,551)   (14,031,196)
Total stockholders’ deficit   (1,245,518)   (750,000)   (393,551)   (2,389,069)
Total Liabilities, Mezzanine Equity and Stockholders’ deficit  $516,600   $-   $51,368   $567,968 

 

Condensed Consolidated Balance Sheet

As of June 30, 2026

(Unaudited)

 

   As Previously Reported   Reclassification   Restatement Adjustment  

As

Restated

 
Accounts receivable  $470,317   $-   $71,945   $542,262 
Inventory   99,051    -    (68,932)   30,119 
Total Assets   814,726   $-   $3,013   $817,739 
Accrued expenses and other current liabilities  $763,195    -   $483,754   $1,246,949 
Promissory notes – related parties   794,787    -    9,692    804,479 
Total current liabilities   1,871,123    -    493,446    2,364,569 
 Mezzanine equity   -    805,000    -    805,000 
 Additional paid-in capital   12,441,491    (805,000)   -    11,636,491 
Accumulated deficit   (13,526,169)   -    (490,433)   (14,016,602)
Total stockholders’ deficit   (1,056,397)   (805,000)   (490,433)   (2,351,830)
Total liabilities, Mezzanine Equity and Stockholders’ deficit  $814,726   $-   $3,013   $817,739 

 

F-11

 

 

NOTE 4 – RELATED PARTY TRANSACTIONS

 

Reprise Management, Inc.

 

On August 13, 2024, as amended on November 8, 2024, Polomar Pharmacy entered into a Promissory Note and Loan Agreement with Reprise Management, Inc. (“Reprise”), as the lender (the “Reprise Note”). Pursuant to the Reprise Note, Reprise agreed to loan Polomar Pharmacy up to $700,000 in one or more advances from time to time. An initial draw under the Reprise Note in the amount of $522,788 was made, which funds were used to repay all amounts due to Reprise pursuant to prior undocumented loans provided by Reprise to Polomar Pharmacy. On June 30, 2025, Reprise exchanged $300,000 of the amount due under the Reprise Note, for sixty (60) shares of the Company’s designated and issued Series A Preferred Stock, par value $0.001 per share. The Reprise Note was amended on July 2, 2025, providing that the remaining principal balance of $597,550 of the Reprise Note shall have an annual interest rate of 12%. Reprise is an affiliate of Daniel Gordon and GLD Partners, LP. (“GLDLP”). Mr. Gordon is the President of Reprise and the majority shareholder of GLD Management, Inc. (“GLD Management”), the general partner of GLDLP, affiliates of which own CWR 1, LLC (“CWR”), and, as such, may be deemed to beneficially own shares held directly by CWR. Mr. Gordon controls approximately 47% of the Company’s voting stock as of September 30, 2026, and December 31,2025. As of September 30, 2026, and December 31, 2025, the Reprise Note outstanding balance, including accrued interest, was $700,969 and $634,870, respectively.

 

See Note 11, subsequent events for an assignment of a Note Payable to Reprise from an unrelated third-party for $450,000.

 

CWR 1, LLC

 

On August 16, 2024, the Company entered into a Promissory Note and Loan Agreement (the “CWR Note”), as the borrower, with CWR as the lender. Pursuant to the CWR Note, CWR agreed to loan the Company up to $250,000 in one or more advances from time to time. An initial draw under the CWR Note in the amount of $157,623 was made, which funds were used to repay CWR all amounts due to CWR pursuant to prior undocumented loans provided by CWR to the Company between January 1, 2024, and August 15, 2024. As of June 30, 2025, the outstanding principal amount of the Note was $450,000, inclusive of accrued interest. On July 2, 2025, the Company and CWR executed an amendment to the CWR Note, effective as of June 30, 2025, CWR exchanged the Note for 90 shares of the Company’s Series A Preferred.

 

On July 21, 2025, the Company entered into a new Promissory Note and Loan Agreement with CWR (“CWR Note II”) with the following terms.

 

  ● The Company may draw up to $150,000. The Company is required to meet certain milestones as fully described in the CWR Note II to draw funds from CWR.
     
  ● The CWR Note II shall mature and be payable in full on or before October 31, 2025, or immediately upon other events as disclosed in the CWR Note II.
     
  ● The initial interest rate shall be 12%, accruing on a quarterly calendar basis. In the event the CWR Note II is not paid in full on or before October 31, 2025, then the interest rate shall be equal to the prime interest rate as published on the first day of each month in the Wall Street Journal – Money Rates plus 7%.

 

On September 17, 2025, the Company and CWR executed an amendment to the CWR Note II (the “CWR II First Amendment”). The CWR II First Amendment increased the principal amount that the Company may draw upon by $150,000 (the “CWR II Additional Principal”) to $300,000. The CWR II Additional Principal has certain restrictions regarding the use of any funds drawn by the Company. The Company may only utilize CWR II Additional Principal for costs associated with the manufacturing and testing of its inhalable sildenafil product. The CWR II Additional Principal shall be subject to a 3% discount per draw. The 3% discount was expensed due to the short-term nature of the debt. All other material terms of CWR Note II remain unchanged.

 

F-12

 

 

The Company drew a total of $248,000 between July 23, 2025, and September 18, 2025, pursuant to the terms of the CWR Note II and has repaid, between December 1, 2025, and February 27, 2026, $263,034 inclusive of all interest and fees. As of September 30, 2026, and December 31, 2025, the CWR Note II was $0 and $62,539, respectively. CWR is an affiliate of Mr. Gordon, and Mr. Gordon beneficially owns or controls approximately 47% of the voting stock of the Company, as of September 30, 2026, and December 31, 2025, respectively. Mr. Gordon and affiliates of Mr. Gordon control approximately 47% of the voting shares of the Company, due to voting rights granted to CWR and Reprise in the Series A Preferred owned by CWR and Reprise as of September 30, 2026, and December 31, 2025, respectively.

 

Profesco Holdings, LLC

 

On July 28, 2025, the Company entered into a Promissory Note and Loan Agreement (the “Profesco Note”) with Profesco Holdings, LLC, a Michigan limited liability company (“Profesco Holdings”). Below is a summary of the terms.

 

  ● The Company may draw up to $100,000 per the terms of the Profesco Note.
     
  ● The Profesco Note matures and is payable in full on or before October 31, 2025, or immediately upon other events as disclosed in the Profesco Note. The initial interest rate is 12%, per annum, accruing on a calendar quarterly basis. In the event the Profesco Note is not paid in full on or before October 31, 2025, then the interest rate shall be equal to the prime interest rate as published on the first day of each month in the Wall Street Journal – Money Rates plus 7%.

 

On November 17, 2025, the Company and Profesco Holdings executed an amendment to the Profesco Note (the “Profesco First Amendment”). Below is a summary of terms.

 

  ● The Profesco First Amendment increased the principal amount that the Company may draw upon by $100,000 (the “Profesco Additional Principal”) to $200,000.
     
  ● The Profesco Additional Principal shall be subject to a 3% origination fee per draw. The annual interest rate to be charged on the Additional Principal shall be 15%, simple interest. The Profesco First Amendment contains provisions for repayment of the Profesco Note between November 1, 2025, and December 31, 2025.
     
  ● Any remaining principal due and owing after January 1, 2026, shall be subject to an 18% annual interest rate. The outstanding balance as of September 30, 2026, and December 31, 2025, for the Profesco Note is $178,545 and $200,251, respectively.

 

Mr. Tierney, the Company’s Interim Chief Executive Officer, is the sole member and manager of Profesco Holdings.

 

Other Related Party Transactions

 

In January of 2026, Polomar Pharmacy purchased 67,800 doses of WafesilTM, a compounded sublingual sildenafil formulation from Orion Specialty Labs, LLC (“Orion”), an FDA registered 503(b) outsourcing facility and the exclusive U.S. distributor of Wafesil. The purchase was for $122,063. Polomar also received 4,200 sample doses of the medication. In June 2026, Polomar Pharmacy purchased 42,240 doses of Wafesil from Orion for $71,280. Orion is controlled by Mr. Gordon, an affiliate of the Company.

 

F-13

 

 

NOTE 5 – NOTE PAYABLE – DIRECTOR AND OFFICER INSURANCE

 

The Company entered into a note payable to finance its directors’ and officers’ insurance policy for $220,720, of which $187,710 was financed. There are nine monthly payments of $21,660 with an interest rate of 9.2% commencing on July 30, 2026, and maturing on March 30, 2027. As of September 30, 2026, the balance outstanding is $148,246.

 

NOTE 6 – MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT

 

Series A Preferred Stock

 

The Company has 5,000,000 shares of “blank check” preferred stock authorized, of which 1,000 shares are designated Series A Preferred, par value $0.001 per share. As of September 30, 2026, and December 31, 2025, 167 and 150 shares were issued and outstanding, respectively, including shares issued as paid-in-kind dividends. All shares are held by CWR 1, LLC and Reprise Management, Inc., affiliates of Mr. Gordon, see Note 4.

 

Each share has a stated value and liquidation preference of $5,000. Dividends are cumulative at 10% per year and are payable quarterly in cash or additional Series A shares. The rate rises to 15% if the Company defaults on a dividend. Holders may convert each share into 12,500 shares of common stock, based on a $0.40 conversion price. The conversion price adjusts downward if the Company issues shares at a lower price. As of September 30, 2026, and December 31, 2025, the outstanding shares were convertible into 2,087,500 and 1,875,000 shares of common stock, respectively.

 

Holders vote with common stockholders as a single class on an as-converted basis, at 0.90 votes per underlying common share. Until shareholder approval is obtained, aggregate Series A voting power is capped at 19.9% of outstanding common stock. Certain significant corporate actions also need the Majority Holder’s consent while the ownership threshold in the Certificate of Designations is met.

 

On liquidation, dissolution, winding-up, or a Change of Control Event (as defined in the Certificate of Designations), holders receive the liquidation preference plus accrued and unpaid dividends before common stockholders receive anything. On a Change of Control Event, that amount is a mandatory cash redemption. Because the redemption is not solely within the Company’s control, the Series A Preferred is classified as mezzanine equity, outside permanent stockholders’ deficit. Its carrying value was $835,000 and $750,000 as of September 30, 2026, and December 31, 2025, respectively.

 

Below is the activity for mezzanine equity for the period January 1, 2025, to September 30, 2026:

 

   Shares   Amount 
Balance, January 01, 2025   -   $- 
Issuance of Series A preferred stock   150    750,000 
Balance, December 31, 2025   150   $750,000 
Paid-in-kind dividend   17    85,000 
Balance, September 30, 2026   167   $835,000 

 

Common Stock

 

The Company is authorized to issue 295,000,000 shares of common stock with a par value of $0.001 as of September 30, 2026, and December 31, 2025, respectively. The Company had 28,380,868 and 28,019,624 issued and outstanding shares of common stock as of September 30, 2026, and December 31, 2025. During the nine months ended September 30, 2026, the Company issued 261,244 shares of common stock for $24,833, or approximately $0.10 per shares. These shares were issued for past services to the Board of Directors that was accrued as of December 31, 2025. In addition, during the three and nine months ended September 30, 2026, 100,000 shares were issued to the Company’s Interim Chief Executive Officer for $11,800, or $0.118 per share.

 

Stock options

 

Stock options are awarded to encourage ownership of the Company’s Common Stock by employees and to provide incentives for employees to render services and to exert maximum effort for the success of the Company. The Company’s incentive stock options generally permit net share settlement upon exercise. The option exercise price, vesting schedule and exercise period are determined for each grant by the administrator (a person appointed by board to administer the stock plans) of the applicable plan. The Company’s stock options generally have a 10-year contractual term.

 

The assumptions used to determine the fair value of options granted for the three and nine months ended September 30, 2026, using the Black-Scholes-Merton model are as follows:

 

Risk-free interest rate  4.27 to 4.31%
Dividend-yield on common stock   0%
Expected volatility (weighted-average and range, if applicable)   110%
Expected term   5.50 to 5.75 years 

 

There were no options granted during the three and nine months ended September 30, 2025.

 

On August 8, 2024, the Company’s stockholders, by written consent of the holders of a majority of the outstanding voting stock, approved the 2024 Equity and Incentive Compensation Plan (the “2024 Plan”). The 2024 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other stock-based awards to employees, officers, directors, consultants and other service providers.

 

The Company initially reserved 5,000,000 shares of common stock for issuance under the 2024 Plan, subject to adjustment for stock splits, stock dividends, recapitalizations, and similar transactions. In addition, the number of shares authorized for issuance under the 2024 Plan is subject to an annual automatic increase on January 1 of each year equal to 10% of the Company’s outstanding common shares, unless the Board of Directors approves a lesser increase, or determines that no increase will be made. On July 1, 2026, the Board amended and restated the plan to (i) reduce the automatic annual “evergreen” increase in the number of shares of common stock authorized for issuance under the plan from ten percent (10%) to three percent (3%) of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, commencing with the increase scheduled for January 1, 2027, (ii) rename the plan the “Polomar Health Services, Inc. 2026 Equity and Incentive Compensation Plan” (the “2026 Plan”), and (iii) make a non-substantive cross-reference correction. Except as so amended, the plan remains in effect in accordance with its terms. As of September 30, 2026, the Company has 9,238,230 shares available under the Plan for future issuances.

 

A summary of the Company’s stock option activities and related information for the nine months ended September 30, 2026, is as follows

 

Stock Option  Number of Stock
Option
   Weighted-Average Exercise Price  

Weighted-

average

remaining

term (years)

  

Aggregate

intrinsic value

 
Balance, January 1, 2026   -   $-    -    - 
Granted   1,329,500    0.17    9.8   $43,134 
Exercised   -    -    -    - 
Forfeited or expired   -    -    -    - 
Balance, September 30, 2026   

1,329,500

   $

0.17

    

9.8

   $43,134 
Vested and expected to vest, September 30, 2026   1,329,500   $0.17    9.8   $43,134 

 

F-14

 

 

The following options were outstanding at their respective exercise price as of September 30, 2026:

 

Exercise Price Options Outstanding  September 30, 2026 
$0.12   829,500 
$0.26   500,000 
Total   1,329,500 

 

As of September 30, 2026, there was $72,297 of unrecognized stock compensation expense related to outstanding stock options. The unrecognized compensation expense is expected to be recognized over a weighted-average period of approximately 1.8 years based on vesting under the award service conditions.

 

NOTE 7 – EARNINGS PER SHARE

 

The schedule of net loss per share, basic and diluted, is as follows:

 

For The Three Months Ended September 30,  2026   2025 
Net loss  $(513,550)  $(649,775)
Dividend on Series A Preferred   (35,500)   - 
Net loss attributable to common shareholders  $(549,050)  $(649,775)
Weighted average shares outstanding – basic and diluted   28,379,781    28,008,183 
Basic and diluted net loss per share  $(0.02)  $(0.02)

 

For The Nine Months Ended September 30,  2026   2025 
Net loss  $(829,002)  $(1,712,193)
Dividend on Series A Preferred   (124,382)   - 
Net loss attributable to common shareholders   (953,384)   (1,712,193)
Weighted average shares outstanding – basic and diluted   28,153,781    27,779,164 
Basic and diluted net loss per share  $(0.03)  $(0.06)

 

Certain share-based equity awards were excluded from the computation of dilutive earnings per share because inclusion of these awards would have had an anti-dilutive effect. The following table reflects the awards that were excluded.

 

             
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2026   2025   2026   2025 
Stock options   1,329,500    -    1,329,500    - 
Conversion of Series A Preferred to common stock   2,087,500    1,875,000    2,087,500    1,875,000 
Total   3,417,000    1,875,000    3,417,000    1,875,000 

 

F-15

 

 

NOTE 8 – REVENUE

 

The following table presents the Company’s revenue disaggregated by type for the three and nine months ended September 30, 2026 and September 30, 2025:

 

       
   Three Months Ended September 30, 
   2026   2025 
Prescription fulfillment  $1,133,775   $- 
Other   -    6,163 
Total  $1,133,775   $6,163 

 

       
   Nine Months Ended September 30, 
   2026   2025 
Prescription fulfillment  $3,739,944   $- 
Other   -    16,174 
Total  $3,739,944   $16,174 

 

NOTE 9 – LEASE

 

The Company has two non-cancellable operating leases, which are recognized as right-of-use assets and lease liabilities under ASC 842, Leases:

 

  ● Manufacturing facility, Palm Harbor, Florida. The lease commenced on June 1, 2026, and expires on May 31,2029. The monthly rent is $3,122.
  ● Corporate office, New York, New York. The lease commenced on August 1, 2026, and expires on July 31, 2028. The monthly rent averages $4,148.

 

As of September 30, 2026, and December 31, 2025, the operating lease asset was $170,379 and $14,864, respectively, and the corresponding operating lease liability was $170,510 and $14,864, respectively.

 

F-16

 

 

The Company evaluates contracts above certain thresholds to identify leases and lease components. Lease and non-lease components are not separated for facility space leases. The Company uses its contractual borrowing rate to determine lease discount rates when an implicit rate is not available. Lease costs for the three and nine months ended September 30, 2026, and September 30, 2025, included in the unaudited condensed consolidated statements of operations, are as follows:

 

             
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
Lease cost  $20,786   $-    $20,786   $-  

 

The following represents the activity for the right of use asset:

 

   September 30, 2026   December 31, 2025 
Beginning balance  $14,864   $49,180 
Additions to operating lease assets   186,586    - 
Amortization    (31,071)   (34,316)
Ending balance  $170,379   $14,864 
           
Other information relating to the operating lease is as follows:          
Weighted average remaining lease term in years   2.3    0.4 
Weighted average discount rate   10%   5.5%

 

Future minimum lease payments as of September 30, 2026 are as follows:

 

Year  Amount 
2026 (remainder of the year)  $21,598 
2027   87,105 
2028   67,006 
2029   15,600 
Total future minimum lease payments   191,309 
Less: imputed interest   (20,799)
Operating lease liabilities   170,510 
Less: current portion   (72,895)
Non-current portion of lease liabilities  $97,615 

 

NOTE 10 – COMMITMENTS AND CONTINGENCIES

 

Employment Agreement

 

On May 12, 2026, the Company and Terrence M. Tierney, the Company’s Interim Chief Executive Officer, executed a First Amendment to Mr. Tierney’s Executive Employment Agreement dated September 15, 2025 (the “First Amendment”). The First Amendment reduced Mr. Tierney’s base salary retroactive to his November 1, 2025 start date to $19,000 per month, subject to increase to $24,000 per month upon the earlier of the Company raising $5,000,000 in new equity or up-listing to a national securities exchange; replaced the prior target bonus with a discretionary annual bonus tied to key performance indicators; modified the severance provisions; and confirmed that 100,000 shares of the Company’s common stock were fully vested as of that date.

 

The First Amendment also amended and restated the option provisions of the employment agreement in their entirety. The previously disclosed option to purchase 1,000,000 shares of common stock at an exercise price of $0.20 per share was never granted or issued and will not be granted, and Mr. Tierney has confirmed in writing that he relinquishes any right to it. In its place, the First Amendment provides for an option to purchase 500,000 shares at an exercise price of $0.26 per share, and two additional options to purchase 500,000 shares each with exercise prices to be determined by formula based on the trailing average closing price of the common stock preceding the applicable grant date, in each case with a ten-year term and vesting 25% on grant with the remainder vesting in equal monthly installments thereafter.

 

During the three months ended September 30, 2026, the Company issued 100,000 shares of common stock to Mr. Tierney, the Company’s Interim Chief Executive Officer, with a grant-date fair value of $0.118 per share, or $11,800. The Company recognized the $11,800 as stock-based compensation expense within general and administrative expenses in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2026.

 

F-17

 

 

License Agreement

 

On June 29, 2024, the Company entered into a Know How and Patent License Agreement with Pinata Holdings, Inc. (“Pinata”), an affiliate of CWR, as restated and amended on January 9, 2025 (the “Agreement”). The Agreement granted the Company a worldwide, non-exclusive, non-transferable license to certain patent-pending intellectual property and know-how related to the delivery of products containing metformin, eletriptan, sumatriptan, semaglutide, liraglutide, and sildenafil, in exchange for royalties of 10% to 20% of net sales of products utilizing the licensed IP. On June 12, 2026, the Company and Pinata mutually agreed to terminate the Agreement.

 

License Agreement Valuation

 

The Company utilized the income approach to value the intellectual property rights licensed from Pinata. The Company, based upon contractual obligations and sales projections provided by For Humanity Health, Inc. projected annual gross revenues through December 31, 2029. During 2025, the Company has elected to accelerate the amortization of its intangible assets of $9,735,000, and the carrying value was zero as of December 31, 2025.

 

The Company has experienced significant delays in bringing the licensed products to market including delays in sourcing active pharmaceutical ingredients, particularly eletriptan, manufacturing, completing required stability and sterility testing, and delays in conducting and completing clinical trials. As a result of these delays and other challenges in marketing products utilizing the IP rights, we and Pinata mutually agreed to terminate the license agreement effective June 12, 2026. Additionally, our former marketing partner, ForHumanity Health, Inc. (“FHH”) expressed concerns regarding efficacy of the inhaled sildenafil product and elected not to pursue an agreement to market the metformin gummy. As a result of these uncertainties and other market conditions we elected to accelerate the amortization of our intangible assets.

 

ForHumanity Agreement

 

On March 11, 2025, Polomar executed a Product Fulfillment and Distribution Agreement, effective on March 12, 2025, as amended on March 17, 2025, and Amended and Restated on August 19, 2025, and as amended on September 23, 2025, and December 8, 2025, with ForHumanity Health, Inc., a Delaware corporation (“FHH”) and Island Group 40, LLC (“I4G”), (collectively, the “ForHumanity Agreement”).

 

The ForHumanity Agreement allowed FHH to exclusively market (through April 30, 2026), Polomar’s previously licensed, patent pending, inhalable sildenafil, marketed as VigorAir™. While sildenafil and eletriptan have been approved by the FDA for prescription use in an oral form and both medications are generally regarded as safe, the FDA has not approved our inhalable compounded formulation. Pursuant to the ForHumanity Agreement, Polomar shall be solely responsible for fulfilling valid prescriptions for the above-referenced medications through Polomar Specialty Pharmacy. I4G provides account management services on behalf of Polomar.

 

The ForHumanity Agreement incorporates the following material terms:

 

  ● The license is for an initial term of forty-two months and may be automatically renewed for additional terms provided FHH meets certain revenue commitments prior to the end of the initial term.

 

F-18

 

 

  ● FHH agreed to a guaranteed payment of $750,000 ($550,000 of which has been received by Polomar as of December 31, 2025).

 

  ● FHH launched test marketing of VigorAir in November 2025. In December 2025 the Company, FHH and Altanine, Inc., the parent of Pinata, sponsored additional clinical trials of our inhaled sildenafil. Preliminary trial results were received by the Company on February 12, 2026, and complete results of the clinical trial were received on February 28, 2026.

 

CareValidate Agreement

 

On September 26, 2025, the Company executed a one-year Pharmacy Services and Compounding Agreement (“Services Agreement”) with CareValidate, Inc. The agreement provides for the Company’s wholly owned subsidiary, Polomar Pharmacy to fill prescriptions for compounded GLP-1 agonists on behalf of CareValidate’s telehealth networks. Polomar Pharmacy began fulfilling prescriptions pursuant to the terms of the Services Agreement on October 6, 2025. CareValidate is Polomar’s only customer. Effective October 1, 2026, the Company executed a new Platform Services Agreement with CareValidate. The agreement is for one year and shall automatically renew for additional years unless either party provides notice of termination at least sixty days prior to the expiration date of the agreement then in effect.

 

Litigation

 

The Company may be involved from time to time in legal proceedings and claims arising in the ordinary course of business. The Company records a liability for loss contingencies when it is probable and reasonably estimable.

 

The Company received a demand letter from FHH relating to matters arising from prior business dealings, to which the Company responded. Since that time, there has been no further communication between the parties. No complaint has been filed, and the Company is not a defendant in any proceeding relating to this matter. Based on the information currently available, management has concluded that the likelihood of a loss is remote and, if a loss were to occur, the amount cannot presently be estimated. Accordingly, no liability has been recorded in the accompanying financial statements as of September 30, 2026. The Company will continue to monitor this matter and will reassess its conclusion and record a liability if warranted if new information becomes available or if the matter progresses to formal legal proceedings.

 

As of September 30, 2026, the Company has had no further communications with FHH regarding the ForHumanity Agreement.

 

NOTE 11 – SUBSEQUENT EVENTS

 

Management has evaluated events and transactions occurring after September 30, 2026, through November 16, 2026, and has identified the following matters requiring disclosure. Unless otherwise noted, these are nonrecognized subsequent events under ASC 855-10 that do not adjust amounts for the financial statements but are material enough to warrant disclosure. 

 

Effective October 15, 2026, independent directors Gabrielle Toledano and Alexandra Peterson resigned as directors of the Company as previously disclosed in the Current Report on Form 8-K filed with the SEC on October 19, 2026. As part of their duties as directors, Ms. Toledano additionally served on the Company’s Compensation Committee and Ms. Peterson served on the Audit Committee. Their decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The three remaining directors each serve on the Audit Committee, Compensation Committee and Nominating and Governance Committee. Mr. George Caruolo is the Audit Committee Chair; Mr. George Hornig is the Compensation Committee Chair and Mr. Gabriel Del Virginia is the Nominating and Governance Committee Chair.

 

On November 1, 2026, pursuant to the Interim Chief Executive Officer’s employment agreement, options were granted to purchase 500,000 shares of common stock. The exercise price is $0.19 per share, 125,000 options vest immediately with the remainder vesting in equal monthly installments over 36 months and expire ten years from the date of grants.

 

Assignment of the Note to a Related Party – Note Payable

 

On November 9, 2026, the Company issued a $450,000 promissory note (the “Note”) to Island 40 Group, LLC (“I4G”). The Note covers commissions the Company owed I4G under a Sales Director and Distribution Agreement. Polomar Specialty Pharmacy, LLC, a wholly owned subsidiary, guarantees the Note. The Note replaced $450,000 of accounts payable owed to I4G, which will be reclassified to notes payable.

 

The Note bears simple interest at 10% per annum through December 31, 2026. After that, the rate is the Wall Street Journal prime rate plus 4%, reset monthly. The Note matures on March 31, 2027, and may be prepaid at any time without penalty. If a bankruptcy or insolvency event occurs, the Note becomes due immediately. For other events of default, I4G may accelerate it. The Note was assigned to Reprise, a related party.

 

F-19

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

 

Forward Looking Statements

 

This quarterly report contains forward-looking statements. Forward-looking statements are projections of events, revenues, income, future economic performance or management’s plans and objectives for our future operations. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” and the risks set out below, any of which may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks include, by way of example and not in limitation:

 

  ● the uncertainty of profitability based upon our history of losses;
  ● legislative or regulatory changes concerning platforms with data about companies;
  ● risks related to failure to obtain adequate financing on a timely basis and on acceptable terms to continue as going concern;
  ● risks related to our operations and uncertainties related to our business plan and business strategy;
  ● changes in economic conditions;
  ● uncertainty with respect to intellectual property rights, protecting those rights and claims of infringement of others’ intellectual property;
  ● competition; and
  ● cybersecurity concerns.

 

This list is not an exhaustive list of the factors that may affect any of our forward-looking statements. These and other factors should be considered carefully, including those contained in our Annual Report on Form 10-K for the year ended December 31, 2025, in each case under “Risk Factors,” and readers should not place undue reliance on our forward-looking statements. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made, and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

 

Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. Our financial statements are stated in United States dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

 

Company Overview

 

The Company, through its subsidiary Polomar Specialty Pharmacy, LLC, operates a Florida-licensed compounding pharmacy that provides both sterile and non-sterile compounded prescription medications and is currently authorized to serve patients in 24 states. Management’s strategic focus is to expand the pharmacy’s geographic reach and capitalize on growing demand for compounded GLP-1 weight-loss therapies and other specialized medications.

 

3

 

 

The Company continues to face operational and financial challenges, including increased compensation and infrastructure costs, investments in regulatory compliance and product development, and the need for additional capital to support growth. While prior supply chain issues have largely been resolved, management remains focused on achieving greater operating scale and improving financial performance.

 

Seasonality

 

Demand for GLP-1 products used for weight management may be subject to seasonal fluctuations. Industry research has identified variations in prescription activity throughout the year, potentially reflecting changes in consumer weight-management goals, patient behavior, and prescribing patterns. Such fluctuations may affect prescription volumes, revenue, and cash flows. However, the extent and timing of any seasonal effects on the Company’s business have not been established and may vary depending on market conditions, patient demand, product availability, and other factors. Accordingly, the Company monitors prescription trends and other operating metrics to assess changes in demand and their potential impact on its financial performance.

 

State Pharmacy Licensing and Regulatory Environment

 

Our ability to compound and dispense prescription products, including compounded GLP-1 products, is dependent upon maintaining pharmacy, nonresident pharmacy, sterile compounding and other applicable licenses and permits in the states in which we operate and into which we dispense or ship products. The regulatory environment for 503A pharmacies continues to evolve, and certain states are imposing or increasing requirements applicable to nonresident pharmacies, including requirements relating to physical presence, pharmacist licensure and oversight, inspections, compounding practices and other state-specific operational requirements. As a result, obtaining and renewing state licenses has become increasingly complex and may require us to modify our operations, establish or maintain additional infrastructure, or incur additional regulatory and compliance costs. In certain jurisdictions, we may be unable to obtain or renew a license if we do not satisfy applicable requirements, which could restrict our ability to dispense or ship products into those states, reduce our addressable market and revenues, increase our operating costs, and adversely affect our business, financial condition and results of operations. We continue to monitor state-specific requirements and evaluate operational and regulatory measures to maintain our existing licenses and preserve access to the markets in which we operate.

 

Results of Operations for the Three Months ended September 30, 2026, compared to the Three Months ended September 30, 2025

 

Revenue

 

Revenue increased by $1,127,612 to $1,133,775 for the three months ended September 30, 2026, from $6,163 for the three months ended September 30, 2025. The increase was attributable to the expansion of the Company’s commercial pharmacy operations and materially higher prescription fulfillment volume. The 2025 period reflected only limited commercial activity.

 

Cost of Goods Sold and Gross Profit

 

Cost of goods sold increased by $617,500 to $619,340 for the three months ended September 30, 2026, from $1,840 for the three months ended September 30, 2025. The increase was attributable to the expansion of the Company’s commercial pharmacy operations and materially higher prescription fulfillment volume, which resulted in higher expenses. The 2025 period reflected only limited commercial activity, and cost of goods sold consisted solely of supplies and materials expense.

 

Gross profit increased by $510,112 to $514,435 for the three months ended September 30, 2026, from $4,323 for the three months ended September 30, 2025, as a result of higher revenue and prescription volume during the period. Gross margin was 45.4% for the three months ended September 30, 2026. Gross margin for the three months ended September 30, 2025, is not considered meaningful because revenue in that period was nominal.

 

General and Administrative Expenses

 

General and administrative expenses decreased by $144,665 to $474,367 for the three months ended September 30, 2026, from $619,032 for the three months ended September 30, 2025. The decrease was primarily attributable to the absence of $249,624 of amortization on the legacy Pinata license intangible, which was fully amortized in 2025, and lower legal and professional fees. The decrease was partially offset by increases in board of director fees by $92,500, investor relations expenses by $79,573, stock-based compensation by $45,262, insurance, and costs associated with utilizing a cloud-based management system designed to support the Company’s 503A compounding pharmacy operations, reflecting the expansion of the Company’s commercial operations and the additional governance, compliance and public-company costs incurred in the current period.

 

4

 

 

Sales and Marketing Expenses

 

Sales and marketing expenses increased by $493,845 to $507,944 for the three months ended September 30, 2026, from $14,099 for the three months ended September 30, 2025. The increase was primarily attributable to commission expense incurred in connection with the Company’s commercial pharmacy operations, for which there was no comparable expense in the 2025 period, together with higher shipping costs resulting from the increase in prescription fulfillment volume during the 2026 period.

 

Other Expense

 

Interest expense increased by $24,707 to $45,674 for the three months ended September 30, 2026, from $20,967 for the three months ended September 30, 2025. The increase was primarily attributable to accounts receivable financing costs, an increase in outstanding related-party borrowings, and interest on the note payable used to finance the Company’s directors and officers’ insurance premium.

 

Nine Months Ended September 30, 2026 Compared to the Nine Months Ended September 30, 2025

 

Revenue

 

Revenue increased by $3,723,770 to $3,739,944 for the nine months ended September 30, 2026, from $16,174 for the nine months ended September 30, 2025. The increase was attributable to the expansion of the Company’s commercial pharmacy operations and substantially higher prescription fulfillment volume during 2026.

 

Cost of Goods Sold and Gross Profit

 

Cost of goods sold increased by $2,037,075 to $2,041,912 for the nine months ended September 30, 2026, from $4,838 for the nine months ended September 30, 2025. The increase was attributable to the expansion of the Company’s commercial pharmacy operations and materially higher prescription fulfillment volume, which resulted in higher supplies and materials, production supplies, payroll-related and testing costs. The 2025 period reflected only limited commercial activity, and cost of goods sold consisted solely of supplies and materials expense.

 

Gross profit increased by $1,686,695 to $1,698,032 for the nine months ended September 30, 2026, from $11,336 for the nine months ended September 30, 2025, as a result of higher revenue and prescription volume during the period. Gross margin was 45.4% for the nine months ended September 30, 2026. Gross margin for the nine months ended September 30, 2025 is not considered meaningful because revenue in that period was nominal.

 

General and Administrative Expenses

 

General and administrative expenses decreased by $844,292 to $744,433 for the nine months ended September 30, 2026, from $1,588,725 for the nine months ended September 30, 2025. The decrease was primarily attributable to amortization of legacy intangible assets, and lower professional fees. Stock-based compensation was also lower in the current period because fewer stock awards were issued in 2026. These decreases were partially offset by board of director fees, investor relations expenses, royalty expenses and costs associated with utilizing a cloud-based management system designed to support the Company’s 503A compounding pharmacy operations, none of which were incurred in the comparable 2025 period, as well as higher insurance and costs reflecting the expansion of the Company’s commercial operations and the additional governance and compliance costs incurred during the period.

 

5

 

 

Sales and Marketing Expenses

 

Sales and marketing expenses increased by $1,640,776 to $1,670,937 for the nine months ended September 30, 2026, from $30,161 for the nine months ended September 30, 2025. The increase was primarily attributable to commission expense of $497,046 incurred in connection with the Company’s commercial pharmacy operations, for which there was no comparable expense in the 2025 period, together with higher shipping costs of $699,161 resulting from the increase in prescription fulfillment volume during the 2026 period. Sales and marketing expenses also included $404,025 of payroll costs, $27,333 of insurance expense and $20,786 of operating lease costs in 2026, for which there was no comparable expense in the 2025 period.

 

Other Expense

 

Interest

 

Interest expense increased by $7,020 to $111,664 for the nine months ended September 30, 2026, from $104,643 for the comparable 2025 period. The increase was primarily attributable to higher financing costs, an increase in outstanding related-party borrowings, and interest on the note payable used to finance the Company’s directors and officers’ insurance premium.

 

Cash Flows

 

Net cash used in operating activities was $586,016 for the nine months ended September 30, 2025. That period’s net loss of $1,712,193 was partly offset by non-cash depreciation and amortization of $777,338 non-cash stock-based compensation expense of $129,658. It was also offset by $200,000 of unearned revenue, a $107,369 increase in accounts payable and accrued liabilities, and a $1,845 decrease in accounts receivable. Working against these was a $90,033 increase in inventory.

 

Operating cash flow improved by $780,012 compared with the prior-year period. The main reasons were an $893,651 larger increase in accounts payable and accrued liabilities and an $883,191 smaller net loss. Inventory also helped: it decreased this year after increasing last year, a swing of $175,133. These gains were partially offset by three non-cash change expense for depreciation and amortization of $758,761, a decrease in unearned revenue of $200,000 and a decrease in counts receivable of $144,609.

 

The Company did not have any cash provided by or used in investing activities for the nine months ended September 30, 2026 or September 30, 2025.

 

Net cash used in financing activities was $71,367 for the nine months ended September 30, 2026, primarily due to repayments of related-party promissory notes of $18,146, payment of a D&O insurance note payable of $39,464 and dividend payments of $13,757. Net cash provided by financing activities was $618,679 for the nine months ended September 30, 2025, due to proceeds from a related-party promissory note.

 

Liquidity and Capital Resources

 

Liquidity refers to the Company’s ability to meet its anticipated cash requirements, including funding ongoing operations, satisfying contractual obligations, and paying other ordinary-course business expenses. The Company’s primary cash requirements consist of operating expenses, general and administrative expenses, payroll, vendor payments, and other costs associated with conducting its business.

 

The Company’s primary sources of liquidity have historically been proceeds from debt and equity financings, together with cash flows generated from operating activities. The Company has relied primarily on external financing to fund its operations and satisfy its working capital requirements.

 

6

 

 

The Company’s ability to meet its future cash requirements will depend on its ability to generate sufficient cash flows from operations, effectively manage operating expenses, and obtain additional financing through debt or equity issuances, as necessary. There can be no assurance that additional financing will be available when required or on terms acceptable to the Company.

 

Management continues to monitor the Company’s cash position, working capital requirements, and operating expenditures and evaluate available financing alternatives to support ongoing operations. If the Company is unable to generate sufficient cash flows from operations or secure additional financing, it may need to reduce or defer certain expenditures, which could adversely affect its business, financial condition, and results of operations.

 

Under Accounting Standards Codification “ASC”, ASC 205-40, Presentation of Financial Statements, Going Concern, management is required to evaluate at each annual and interim reporting period whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued, and, if substantial doubt is raised, whether our plans to mitigate those conditions, when considered in the aggregate, alleviate that doubt.

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

 

Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the financial statements are issued and determined that substantial doubt exists about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on the Company’s ability to generate revenue, raise capital and the ability to meet its obligations as they become due, within a year from the date of issuance of these financial statements. Management assessed that there were such conditions and events, including a history of recurring operating losses, a history of negative cash flows from operating activities, and significant current debt. As of September 30, 2026, the Company has cash and cash equivalents of $254,779 and an accumulated deficit of $14,565,652. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date of filing of the financial statements. Management’s plans are to raise additional capital, explore potential business opportunities, and to increase revenue. However, there is no assurance that the Company will raise sufficient capital to continue operations or be on acceptable terms. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Critical Accounting Estimates

 

As of September 30, 2026, there were no significant changes in the application or the nature of accounting estimates that are considered critical in nature from those presented in our Annual Report on Form 10-K.

 

Smaller Reporting Company

 

We are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K, which allows us to take advantage of certain scaled disclosure requirements, including, among other things, presenting only two years of audited financial statements and providing reduced executive compensation disclosure. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our Common Stock held by non-affiliates equals or exceeds $250.0 million as of the prior June 30, and (ii) either our annual revenues equaled or exceeded $100.0 million during the most recently completed fiscal year or the market value of our Common Stock held by non-affiliates equals or exceeds $700.0 million as of the prior June 30. In addition, because we are a non-accelerated filer, we are not required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. If we become an accelerated filer or a large accelerated filer, we will be required to obtain an attestation report from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. To the extent we take advantage of such reduced disclosure obligations, it may make comparisons of our financial statements with those of other public companies difficult or impossible.

 

7

 

 

Related Party Transactions

 

See Note 4, to the accompanying unaudited condensed financial statements for related party transactions.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e). The evaluation was conducted under the supervision and with the participation of our Interim Chief Executive Officer and our Chief Financial Officer. Based on that evaluation, they concluded that our disclosure controls and procedures were not effective as of September 30, 2026. This conclusion results from the material weaknesses in our internal control over financial reporting described below, including the material weaknesses that led to the restatement of our previously issued financial statements.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting that creates a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Material Weaknesses in Internal Control over Financial Reporting

 

Management concluded that the Company’s internal control over financial reporting was not effective due to the existence of the following material weaknesses:

 

  ●Insufficient segregation of duties due to a limited number of accounting and finance personnel.

 

  ●An insufficient complement of personnel possessing the appropriate level of accounting, financial reporting, and SEC reporting expertise necessary to ensure the timely preparation and review of financial statements and related disclosures in accordance with U.S. GAAP and the requirements of the SEC.

 

  ● Limited independent oversight by the Board of Directors resulting from an insufficient number of independent directors.
     
  ● Inadequate documentation of accounting policies, internal control procedures, and corporate governance processes.
     
  ● Insufficient review controls over the preparation and review of financial statements, SEC filings, significant accounting estimates, and related disclosures.
     
  ● Inadequate employee and director training regarding internal controls, corporate governance, ethics, and compliance responsibilities.
     
  ● Limited monitoring activities to assess whether internal controls were operating effectively on an ongoing basis.

 

These material weaknesses resulted in the restatement described below and create a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Restatement of Previously Issued Financial Statements

 

As described in Note 3 to the unaudited condensed consolidated financial statements in this Quarterly Report, management identified errors in our previously issued financial statements while preparing the financial statements for the three and nine months ended September 30, 2026. The affected financial statements are those for the three months ended March 31, 2026, and for the three and six months ended June 30, 2026 (the “Non-Reliance Periods”). The errors related to:

 

  ● commissions and purchases that were incurred but not recorded;
  ● expenses improperly recorded to inventory;
  ● revenue recorded in the incorrect period; and
  ● classification of the Series A Preferred Stock as stockholders’ equity rather than mezzanine equity.

 

Correcting these errors increased the net loss by $393,551 for the three months ended March 31, 2026, and decreased the net income by $96,882 for the three months ended June 30, 2026, an increase in the net loss of $490,433 for the six months ended June 30, 2026. Reclassifying the Series A Preferred Stock to mezzanine equity had no effect on net loss.

 

8

 

 

On November 1, 2026, the Audit Committee of the Board of Directors concluded, after discussion with management, that the financial statements for the Non-Reliance Periods should no longer be relied upon. The Company disclosed this conclusion in a Current Report on Form 8-K filed on November 3, 2026. Management has concluded that these errors resulted from the material weaknesses described above, specifically those over the financial close and review process and the accounting for complex financial instruments.

 

Separately, during the three months ended September 30, 2026, the Company changed how it presents cost of goods sold, general and administrative expenses, and selling and marketing expenses. Prior-period amounts were reclassified to conform to the current presentation. This reclassification is a change in presentation, not the correction of an error. It had no effect on previously reported net loss, net loss per share, total assets, total liabilities, stockholders’ deficit or cash flows.

 

Remediation of Material Weaknesses

 

Beginning July 1, 2026, the Company initiated a number of actions intended to remediate the material weaknesses described above:

 

  ● The Company strengthened its senior management team by appointing an Executive Director and hiring a Chief Financial Officer with significant experience serving as the chief financial officer of several public companies. The Company also hired a Controller. These actions are intended to enhance the Company’s financial reporting capabilities and improve segregation of duties within the accounting and finance function.

 

In addition, the Company updated and formalized its written corporate governance policies and procedures, including accounting policies, internal control documentation, approval authority matrices, disclosure controls and procedures, and financial reporting processes. The Company also implemented formal training programs for employees and directors covering internal control responsibilities, financial reporting, SEC compliance, corporate governance, ethics, and related compliance matters.

 

Management believes these actions will strengthen the Company’s control environment. However, the material weaknesses will not be considered remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are designed and operating effectively. Accordingly, as of September 30, 2026, the material weaknesses described above had not been remediated. Management will continue to monitor the effectiveness of these remediation efforts and may take additional measures as appropriate.

 

Changes in Internal Control over Financial Reporting

 

Except for the remediation activities described above, there were no changes in our internal control over financial reporting during the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

9

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not a party to any pending legal proceedings. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A. Risk Factors

 

In addition to the other information in this Quarterly Report, you should carefully consider the risk factors in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on May 22, 2026 (the “2025 Form 10-K”). The risk factors below supplement, and should be read together with, those in the 2025 Form 10-K. Except as set forth below, there have been no material changes to the risk factors disclosed in the 2025 Form 10-K.

 

We have restated our unaudited condensed consolidated financial statements for the quarters ended March 31, 2026 and June 30, 2026, which could harm investor confidence, the market for our common stock and our ability to raise capital, and could expose us to litigation or regulatory proceedings.

 

On November 1, 2026, the Audit Committee of our Board of Directors, after discussion with management, concluded that our unaudited condensed consolidated financial statements for the three months ended March 31, 2026, and the three and six months ended June 30, 2026, should no longer be relied upon. We disclosed this conclusion in our Current Report on Form 8-K filed on November 3, 2026. The errors in those periods related to:

 

  ● commissions, purchases and interest expense that were incurred but not recorded;
  ● expenses improperly recorded to inventory;
  ● revenue recorded in the incorrect period; and
  ● the classification of our Series A Preferred Stock as stockholders’ equity rather than temporary (mezzanine) equity.

 

Correcting these errors increased our net loss by $393,551 for the three months ended March 31, 2026, and by $96,882 for the three months ended June 30, 2026. We intend to file amended Quarterly Reports on Form 10-Q/A restating these periods as soon as practicable, see Note 3 to our unaudited condensed consolidated financial statements included in this Quarterly Report.

 

The restatement has required significant time and attention from our management and our small accounting and finance team, and preparing the amended Quarterly Reports will continue to do so. It has also caused us to incur unanticipated accounting, legal and other professional fees. The restatement could cause investors, lenders, customers and business partners to lose confidence in the reliability of our financial reporting. That loss of confidence could reduce the market price and liquidity of our common stock and make it more difficult or costly for us to obtain financing. This risk is heightened because, as described in Note 2, there is substantial doubt about our ability to continue as a going concern, and our ability to continue operating depends on raising additional capital. Until the amended Quarterly Reports are filed, our ability to access the capital markets may also be limited. In addition, the restatement may increase the cost of our directors’ and officers’ liability insurance and make it more difficult to attract and retain qualified directors and officers.

 

Although we are not currently a party to any legal proceedings, we could become subject to stockholder lawsuits, inquiries or investigations by the SEC or other regulatory authorities, or other claims relating to the restatement or the material weaknesses described in Part I, Item 4. Any such matter, regardless of its merit or outcome, could result in substantial costs and divert management’s attention. It could also result in damages, fines or penalties that may not be covered by insurance.

 

We also cannot assure you that additional errors will not be identified, whether in preparing the amended Quarterly Reports, in the audit of our financial statements for the year ending December 31, 2026, or otherwise. Nor can we assure you that we will not be required to restate other previously issued financial statements.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

As of November 16, 2026, the Company issued 100,000 shares of common stock to its Interim Chief Executive Officer as compensation pursuant to the amended employment agreement. The shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering. The shares had a grant-date fair value of $0.118 per share, or an aggregate fair value of $11,800, which was recognized as stock-based compensation expense.

 

Item 3. Defaults Upon Senior Securities

 

On July 28, 2025, the Company entered into a Promissory Note and Loan Agreement, as amended on November 17, 2025 (the “Profesco Note”), with Profesco Holdings, LLC (“Profesco Holdings”). Profesco Holdings is a related party, wholly owned and managed by Mr. Tierney, the Company’s Interim Chief Executive Officer. Under the Profesco Note, as amended, the outstanding balance was required to be repaid by December 31, 2025. The Company did not repay the outstanding balance by that date, and the Profesco Note has been in default since January 1, 2026. Following the default, the outstanding balance accrues interest at 18% per annum.

 

As of September 30, 2026, the outstanding balance under the Profesco Note was $178,545, including accrued and unpaid interest. As of the date of this report, Profesco Holdings has not provided notice to accelerate the obligation, and no waiver or forbearance agreement has been carried out. See Note 4, to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

Director Resignations

 

On October 15, 2026, Alexandra Peterson notified the Board of her resignation as a director of the Company, effective October 15, 2026. At the time of her resignation, Ms. Peterson served as a member of the Audit committee of the Board.

 

On October 15, 2026, Gabrielle Toledano notified the Board of her resignation as a director of the Company, effective October 15, 2026. At the time of her resignation, Ms. Toledano served as a member of the Compensation Committee of the Board.

 

Neither Ms. Peterson’s nor Ms. Toledano’s decision to resign was the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

 

On October 15, 2026, the Board reduced the size of the Board from five to three directors, effective upon the effectiveness of the resignations. The Board consists of three directors: George Hornig, George Caruolo, and Gabriel Del Virginia.

 

Rule 10b5-1 Trading Arrangements

 

During the three months ended September 30, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

 

Item 6. Exhibits

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

No.   Description of Exhibit
3.1*   Amended and Restated Bylaws of Polomar Health Services, Inc., effective July 1, 2026
10.1*   Polomar Health Services, Inc. 2026 Equity and Incentive Compensation Plan (as amended and restated effective July 1, 2026)
10.2*   Promissory Note and Loan Agreement Effective November 9, 2026, between Island 40 Group. LLC and Polomar Health Services, Inc.
31.1*   Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
31.2*   Certification of Chief Financial Officer and Treasurer and Principal Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1**   Certificate of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certificate of Chief Accounting Officer and Accounting Principal Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*   Inline XBRL Instance Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.
** Furnished.

 

10

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Polomar Health Services, Inc.  
     
By: /s/ Terrence M. Tierney  
  Terrence M. Tierney  
Title: Interim Chief Executive Officer  
  (Principal Executive Officer)  
  November 16, 2026  
     
By: /s/ Douglas Beck  
  Douglas Beck  
Title: Chief Financial Officer and Treasurer  
  (Principal Financial and Accounting Officer)  
  November 16, 2026  

 

11

Keep reading